GlassScriptPhysician profile
Jad A Donato
NPI 1356791503
$1,149.10
in general payments reported to CMS, 2019-2025
19 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.99 · 2022: $139 · 2023: $175 · 2024: $392 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.72 | 2023-2025 | Botox, Ubrelvy |
| Lundbeck LLC | $177.52 | 2022-2025 | Vyepti, Rexulti |
| Ucb, INC. | $152.90 | 2023-2025 | Briviact, Nayzilam |
| Pfizer INC. | $115.02 | 2023-2025 | |
| Sk Life Science, INC. | $105.23 | 2022-2025 | |
| Lilly USA, LLC | $71.29 | 2022-2024 | Reyvow, Emgality |
| Otter Pharmaceuticals, LLC | $45.56 | 2025 | Sympazan |
| Jazz Pharmaceuticals INC. | $43.81 | 2023 | |
| Aucta Pharmaceuticals, INC. | $39.70 | 2024-2025 | Motpoly Xr |
| Neurelis, INC. | $37.96 | 2023-2024 | Valtoco |
| Supernus Pharmaceuticals, INC. | $19.01 | 2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.68 | 2025 | |
| Amneal Pharmaceuticals LLC | $18.34 | 2025 | Brekiya |
| Tris Pharma INC | $15.99 | 2025 | Onyda Xr |
| Impel Pharmaceuticals INC. | $15.54 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.01 | 2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $13.62 | 2022 | |
| Csl Behring | $13.21 | 2024 | Hizentra |
| Biohaven Pharmaceuticals, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jad Donato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.